Andrzej Jakubowiak

20PUBLICATIONS
109CO-AUTHORS
Medical mycologyGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 23, 2026
Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma.

|May 27, 2026
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.

|Jan 21, 2026
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.

Melissa Alsina, Nina Shah, Sundar Jagannath

|Jul 17, 2025
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma.

Ola Landgren, Noa Biran, Elizabeth K O'Donnell

|Jun 03, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.

Sundar Jagannath, Thomas G Martin, Yi Lin

|Jul 08, 2024
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.

Ajai Chari, Jonathan L Kaufman, Jacob Laubach

Pageof 4

Frequent Collaborators

10 joint publications

Benjamin Derman

5 joint publications

Saad Z Usmani

4 joint publications

Tadeusz Kubicki

4 joint publications

Jonathan L Kaufman